Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Whooping Cough Vaccination Rates Stay the Same Despite Epidemic

by Global Biodefense Staff
May 5, 2014
Biodefense Vaccine Development

Credit: Shutterstock

DTAP VaccineConventional wisdom holds that when the risk of catching a disease is high, people are more likely to get vaccinated to protect themselves. This may not be the case, however, according to a study presented today at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

Researchers, led by Elizabeth R. Wolf, MD, FAAP, compared rates of infant vaccination with the diphtheria, tetanus and pertussis vaccine (DTaP) before and during an epidemic of pertussis (whooping cough) in Washington state. Surprisingly, they found no difference in vaccination rates.

“We have always assumed that when the risk of catching a disease is high, people will accept a vaccine that is effective in preventing that disease. Our results may challenge this assumption,” said Dr. Wolf, the Ruth L. Kirschstein National Research Service Award Fellow in General Academic Pediatrics at University of Washington, Seattle Children’s Research Institute.

Washington state experienced a pertussis epidemic from Oct. 1, 2011, through Dec. 31, 2012, and infants were hit the hardest. The highly contagious bacterial disease causes uncontrollable, violent coughing that can make it hard to breathe. Pertussis also is known as whooping cough because a “whooping” sound often is heard when the patient tries to take a breath. Pertussis can lead to pneumonia, seizures (jerking and staring spells), brain damage and death.

Dr. Wolf and her colleagues compared the proportion of 3- to 8-month-olds who had received the recommended number of doses of pertussis-containing vaccine before the epidemic and during the epidemic. Infants who received at least one dose by 3 months of age, at least two doses by 5 months and at least three doses by 7 months are considered up to date by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.

“We hypothesized that a whooping cough epidemic would result in more parents getting their children immunized against whooping cough,” Dr. Wolf said. “But compared to a time before the 2011-2012 whooping cough epidemic in Washington state, there was no significant increase in receipt of whooping cough vaccines for infants during the epidemic.”

Results did show considerable variability in vaccination rates among different counties.

“Vaccination rates in the U.S. are still below public health goals,” Dr. Wolf noted. “We don’t fully understand what improves vaccine acceptance. This study found no significant increase in vaccination coverage statewide during the 2011-2012 pertussis epidemic. This finding may challenge the assumption that vaccine acceptance uniformly increases when risk of disease is high.”

The study was funded by a grant from the National Institutes of Health.

Tags: NIHVaccinesWhooping Cough

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC